AI Article Synopsis

  • Patients with Glycogen Storage Disease Type IIIa (GSD IIIa) experience muscle wasting and exercise intolerance, likely due to issues with glycogen metabolism and insufficient carbohydrate oxidation.
  • A study of six participants showed that their peak oxygen consumption (VO2peak) was below normal, and glucose infusion significantly improved their exercise capacity by increasing peak work rate and reducing heart rate.
  • The research indicates that GSD IIIa symptoms should not only be viewed as related to muscle wasting but also include dynamic symptoms like fatigue and weakness caused by inadequate energy production during exercise.

Article Abstract

Myopathic symptoms in Glycogen Storage Disease Type IIIa (GSD IIIa) are generally ascribed to the muscle wasting that these patients suffer in adult life, but an inability to debranch glycogen likely also has an impact on muscle energy metabolism. We hypothesized that patients with GSD IIIa can experience exercise intolerance due to insufficient carbohydrate oxidation in skeletal muscle. Six patients aged 17-36-years were studied. We determined VO 2peak (peak oxygen consumption), the response to forearm exercise, and the metabolic and cardiovascular responses to cycle exercise at 70% of VO 2peak with either a saline or a glucose infusion. VO 2peak was below normal. Glucose improved the work capacity by lowering the heart rate, and increasing the peak work rate by 30% (108 W with glucose vs. 83 W with placebo, p=0.018). The block in muscle glycogenolytic capacity, combined with the liver involvement caused exercise intolerance with dynamic skeletal muscle symptoms (excessive fatigue and muscle pain), and hypoglycemia in 4 subjects. In this study we combined anaerobic and aerobic exercise to systematically study skeletal muscle metabolism and exercise tolerance in patients with GSD IIIa. Exercise capacity was significantly reduced, and our results indicate that this was due to a block in muscle glycogenolytic capacity. Our findings suggest that the general classification of GSD III as a glycogenosis characterized by fixed symptoms related to muscle wasting should be modified to include dynamic exercise-related symptoms of muscle fatigue. A proportion of the skeletal muscle symptoms in GSD IIIa, i.e. weakness and fatigue, may be related to insufficient energy production in muscle.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymgme.2013.02.008DOI Listing

Publication Analysis

Top Keywords

gsd iiia
16
skeletal muscle
16
exercise intolerance
12
muscle
12
exercise
8
glycogen storage
8
storage disease
8
disease type
8
muscle wasting
8
patients gsd
8

Similar Publications

Article Synopsis
  • Glycogen storage disorder type IIIa is a rare genetic condition affecting the liver and muscles, where liver transplantation can help with metabolic control but does not address muscle issues.
  • A case study describes a 31-year-old man who had a liver transplant for end-stage liver disease due to GSD type IIIa, but afterward, he experienced worsening muscle pain and elevated enzyme levels linked to muscle involvement rather than the liver.
  • The increase in muscle symptoms post-transplant may be due to improved liver function which led to excess glucose in the muscle cells, and while a high-protein ketogenic diet was attempted, it did not significantly help the patient's muscle pain.
View Article and Find Full Text PDF

Dietary lipid manipulation has recently been proposed for managing glycogen storage disease (GSD) type IIIa. This study aimed to evaluate the myopathic, cardiac, and metabolic status, physical activity, growth, and dietary compliance of a personalized diet high in protein and fat for 24 months. Of 31 patients with type IIIa GSD, 12 met the inclusion criteria.

View Article and Find Full Text PDF

Glycogen storage disease Type III (GSD III) is an autosomal recessive disease due to the deficiency of the debranching enzyme, which has two main consequences: a reduced availability of glucose due to the incomplete degradation of glycogen, and the accumulation of abnormal glycogen in liver and cardiac/skeletal muscle. The role of dietary lipid manipulations in the nutritional management of GSD III is still debated. A literature overview shows that low-carbohydrate (CHO) / high-fat diets may be beneficial in reducing muscle damage.

View Article and Find Full Text PDF

Anesthetic management for dental surgery in a child with glycogen storage disease type IIIa: a case report.

J Dent Anesth Pain Med

December 2022

Baskent University, Faculty of Medicine, Department of Anesthesiology, Ankara, Turkey.

Glycogen storage disease (GSD) is a group of inherited disorders, which result in the deficiency of enzymes involved in glycogen metabolism, leading to an accumulation of glycogen in various organs. Deficiency of amylo-1-6-glicosidase (debranching enzyme) causes glycogen storage disease type III (GSD III). The main problems that anesthesiologists face in patients with GSD III include hypoglycemia, muscle weakness, delayed awakening due to abnormal liver function, possible difficulty in airway, and cardiomyopathy.

View Article and Find Full Text PDF

Glycogen debranching enzyme deficiency in glycogen storage disease type III (GSD III) results in excessive glycogen accumulation in multiple tissues, primarily the liver, heart, and skeletal muscle. We recently reported that an adeno-associated virus vector expressing a bacterial debranching enzyme (pullulanase) driven by the ubiquitous CMV enhancer/chicken β-actin (CB) promoter cleared glycogen in major affected tissues of infant GSD IIIa mice. In this study, we developed a potentially novel dual promoter consisting of a liver-specific promoter (LSP) and the CB promoter for gene therapy in adult GSD IIIa mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!